Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 2
1975 7
1976 2
1977 2
1978 6
1979 5
1980 6
1981 3
1982 8
1983 12
1984 12
1985 6
1986 10
1987 8
1988 13
1989 17
1990 19
1991 20
1992 18
1993 26
1994 26
1995 32
1996 17
1997 37
1998 24
1999 34
2000 28
2001 55
2002 33
2003 42
2004 45
2005 45
2006 45
2007 40
2008 41
2009 34
2010 38
2011 37
2012 48
2013 46
2014 52
2015 55
2016 55
2017 49
2018 45
2019 46
2020 46
2021 80
2022 77
2023 66
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

1,392 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Mixed Cellularity Classic Hodgkin Lymphoma"
Page 1
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Connors JM, et al. Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. Nat Rev Dis Primers. 2020. PMID: 32703953 Review.
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. ...Diagnosis is based on histological and immunohistochemical analyses of tissue from a lymph node biopsy; the t …
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in t …
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Mei MG, et al. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. Blood. 2022. PMID: 35316328 Free PMC article. Clinical Trial.
This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin lympho …
This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salva …
Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Fan Z, et al. Am J Surg Pathol. 2003 Oct;27(10):1346-56. doi: 10.1097/00000478-200310000-00007. Am J Surg Pathol. 2003. PMID: 14508396
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow-up was obtained on 56 patients, including 26 patients who had not had recurrence of disease and 30 patients who had recurr …
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow …
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. LaCasce AS, et al. Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27. Blood. 2018. PMID: 29703778 Free PMC article. Clinical Trial.
Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts …
Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refr …
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Herrera AF, et al. Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11. Blood. 2018. PMID: 29229594 Free PMC article. Clinical Trial.
In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of combinatio …
In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy …
Hodgkin's lymphoma in adults.
Townsend W, Linch D. Townsend W, et al. Lancet. 2012 Sep 1;380(9844):836-47. doi: 10.1016/S0140-6736(12)60035-X. Epub 2012 Jul 25. Lancet. 2012. PMID: 22835602 Free article. Review.
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease are excellent, and serial reductions in intensity of treatment have been made to retain the excellent prognosis while reducing the late effe …
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease …
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin's lymphoma (HL) after autologous stem-cell transplantation (auto-SCT). ...The media …
PATIENTS AND METHODS: In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in pa …
Primary pulmonary lymphoma.
Graham BB, Mathisen DJ, Mark EJ, Takvorian RW. Graham BB, et al. Ann Thorac Surg. 2005 Oct;80(4):1248-53. doi: 10.1016/j.athoracsur.2005.04.014. Ann Thorac Surg. 2005. PMID: 16181848
Fourteen patients had mucosa-associated lymphoid tissue (MALT) lymphoma, 2 had large cell transformation of sheet cells in MALT lymphoma, and 1 each had Hodgkin's disease and follicular lymphoma. ...Patients who had bilateral disease were …
Fourteen patients had mucosa-associated lymphoid tissue (MALT) lymphoma, 2 had large cell transformation of sheet cells in MALT ly …
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.
van Bladel DAG, Stevens WBC, Kroeze LI, de Groen RAL, de Groot FA, van der Last-Kempkes JLM, Berendsen MR, Rijntjes J, Luijks JACW, Bonzheim I, van der Spek E, Plattel WJ, Pruijt JFM, de Jonge-Peeters SDPWM, Velders GA, Lensen C, van Bladel ER, Federmann B, Hoevenaars BM, Pastorczak A, van der Werff Ten Bosch J, Vermaat JSP, Nooijen PTGA, Hebeda KM, Fend F, Diepstra A, van Krieken JHJM, Groenen PJTA, van den Brand M, Scheijen B. van Bladel DAG, et al. Blood Adv. 2023 Oct 10;7(19):5911-5924. doi: 10.1182/bloodadvances.2023010412. Blood Adv. 2023. PMID: 37552109 Free PMC article.
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is underinvestigated. To analyze the nature of …
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represent …
Next-generation surveillance strategies for patients with lymphoma.
Cohen JB, Kurtz DM, Staton AD, Flowers CR. Cohen JB, et al. Future Oncol. 2015;11(13):1977-91. doi: 10.2217/fon.15.92. Future Oncol. 2015. PMID: 26161931 Free PMC article. Review.
While remission and cure rates for Hodgkin and non-Hodgkin lymphoma continue to improve, surveillance approaches remain controversial, especially in light of recent reports suggesting limited benefit for routine radiologic assessment. ...This review discusses …
While remission and cure rates for Hodgkin and non-Hodgkin lymphoma continue to improve, surveillance approaches remain …
1,392 results